Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002;347:1557–65. https://doi.org/10.1056/NEJMoa021993.
Article CAS PubMed Google Scholar
Libby P. The changing landscape of atherosclerosis. Nat. 2021;592:524–33. https://doi.org/10.1038/s41586-021-03392-8.
Martínez GJ, Robertson S, Barraclough J, et al. Colchicine acutely suppresses local cardiac production of inflammatory cytokines in patients with an acute coronary syndrome. J Am Heart Assoc. 2015;4:e002128. https://doi.org/10.1161/jaha.115.002128.
Article PubMed PubMed Central Google Scholar
Ridker PM, Howard CP, Walter V, et al. Effects of interleukin-1β inhibition with canakinumab on hemoglobin A1c, lipids, C-reactive protein, interleukin-6, and fibrinogen: a phase IIb randomized, placebo-controlled trial. Circ. 2012;126:2739–48. https://doi.org/10.1161/circulationaha.112.122556.
Tardif JC, Kouz S, Waters DD, et al. Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019;381:2497–505. https://doi.org/10.1056/NEJMoa1912388.
Article CAS PubMed Google Scholar
Nidorf SM, Fiolet ATL, Mosterd A, et al. Colchicine in Patients with chronic coronary disease. N Engl J Med. 2020;383:1838–47. https://doi.org/10.1056/NEJMoa2021372.
Article CAS PubMed Google Scholar
Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372:2387–97. https://doi.org/10.1056/NEJMoa1410489.
Article CAS PubMed Google Scholar
Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376:1713–22. https://doi.org/10.1056/NEJMoa1615664.
Article CAS PubMed Google Scholar
Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med. 2018;379:2097–107. https://doi.org/10.1056/NEJMoa1801174.
Article CAS PubMed Google Scholar
Hutton B, Salanti G, Caldwell DM, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med. 2015;162:777–84. https://doi.org/10.7326/m14-2385.
Higgins JP, Altman DG, Gøtzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928. https://doi.org/10.1136/bmj.d5928.
Article PubMed PubMed Central Google Scholar
Krahn U, Binder H, König J. A graphical tool for locating inconsistency in network meta-analyses. BMC Med Res Methodol. 2013;13:35. https://doi.org/10.1186/1471-2288-13-35.
Article PubMed PubMed Central Google Scholar
Rücker G, Schwarzer G. Ranking treatments in frequentist network meta-analysis works without resampling methods. BMC Med Res Methodol. 2015;15:58. https://doi.org/10.1186/s12874-015-0060-8.
Article PubMed PubMed Central Google Scholar
Nidorf SM, Eikelboom JW, Budgeon CA, Thompson PL. Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013;61:404–10. https://doi.org/10.1016/j.jacc.2012.10.027.
Article CAS PubMed Google Scholar
Tong DC, Quinn S, Nasis A, et al. Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020;142:1890–900. https://doi.org/10.1161/circulationaha.120.050771.
Akrami M, Izadpanah P, Bazrafshan M, et al. Effects of colchicine on major adverse cardiac events in next 6-month period after acute coronary syndrome occurrence; a randomized placebo-control trial. BMC Cardiovasc Disord. 2021;21:583. https://doi.org/10.1186/s12872-021-02393-9.
Article CAS PubMed PubMed Central Google Scholar
Ako J, Hibi K, Tsujita K, et al. Effect of Alirocumab on coronary atheroma volume in Japanese Patients with acute coronary syndrome- the ODYSSEY J-IVUS trial. Circ J. 2019;83:2025–33. https://doi.org/10.1253/circj.CJ-19-0412.
Article CAS PubMed Google Scholar
Räber L, Ueki Y, Otsuka T, et al. Effect of alirocumab added to high-intensity statin therapy on coronary atherosclerosis in patients with acute myocardial infarction: the PACMAN-AMI randomized clinical trial. Jama. 2022;327:1771–81. https://doi.org/10.1001/jama.2022.5218.
Article CAS PubMed PubMed Central Google Scholar
Ray KK, Wright RS, Kallend D, et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. N Engl J Med. 2020;382:1507–19. https://doi.org/10.1056/NEJMoa1912387.
Article CAS PubMed Google Scholar
Ridker PM, Revkin J, Amarenco P, et al. Cardiovascular efficacy and safety of bococizumab in high-risk patients. N Engl J Med. 2017;376:1527–39. https://doi.org/10.1056/NEJMoa1701488.
Article CAS PubMed Google Scholar
Hagiwara N, Kawada-Watanabe E, Koyanagi R, et al. Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. Eur Heart J. 2017;38:2264–76. https://doi.org/10.1093/eurheartj/ehx162.
Article CAS PubMed PubMed Central Google Scholar
Tsujita K, Sugiyama S, Sumida H, et al. Impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on coronary plaque regression in patients with percutaneous coronary intervention: the multicenter randomized controlled PRECISE-IVUS trial. J Am Coll Cardiol. 2015;66:495–507. https://doi.org/10.1016/j.jacc.2015.05.065.
Cannon CP, Cariou B, Blom D, et al. Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statin: the ODYSSEY COMBO II randomized controlled trial. Eur Heart J. 2015;36:1186–94. https://doi.org/10.1093/eurheartj/ehv028.
Article CAS PubMed PubMed Central Google Scholar
Ray KK, Bays HE, Catapano AL, et al. Safety and efficacy of bempedoic acid to reduce LDL cholesterol. N Engl J Med. 2019;380:1022–32. https://doi.org/10.1056/NEJMoa1803917.
Article CAS PubMed Google Scholar
Goldberg AC, Leiter LA, Stroes ESG, et al. Effect of bempedoic acid vs placebo added to maximally tolerated statin on low-density lipoprotein cholesterol in patients at high risk for cardiovascular disease: the CLEAR Wisdom randomized clinical trial. Jama. 2019;322:1780–8. https://doi.org/10.1001/jama.2019.16585.
Article CAS PubMed PubMed Central Google Scholar
Kelly PJ, Lemmens R, Tsivgoulis G. Inflammation and stroke risk: a new target for prevention. Stroke. 2021;52:2697–706. https://doi.org/10.1161/strokeaha.121.034388.
Swerdlow DI, Holmes MV, Kuchenbaecker KB, et al. The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet. 2012;379:1214–24. https://doi.org/10.1016/s0140-6736(12)60110-x.
Ference BA, Ginsberg HN, Graham I, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel. Eur Heart J. 2017;38:2459–72. https://doi.org/10.1093/eurheartj/ehx144.
留言 (0)